Worth reading
58In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Avoiding a definitive answer
How definitive the wording is.Revised forecast
Fiscal year ending June 2026 · Full yearPrevious forecast published 2025 年 8 月 13 日Net Sales—→4,000million
—
Operating profit—→50million
—
Ordinary income—→55million
—
Profit attributable to owners of the parent—→30million
—
Net income per share—→1.15yen and sen
—
The bar length represents the relative magnitude of change, based on the item that changed the most in this document.
Reason for the revision
構造改革を継続し、医療DXを中心としたヘルスケア事業領域への経営資源の集中、健康補助食品事業の強化、事業ポートフォリオの再構築を進める。子会社の事業活動終了方針や希望退職制度の実施決定を踏まえ、セグメント別の受注・販売戦略・コスト改善などを反映して業績予想を公表した。
Previous-period results売上高 4,848 百万円、営業利益 △137 百万円、経常利益 △129 百万円、親会社株主に帰属する当期純利益 △210 百万円、１株当たり当期純利益 △8.05 円 銭（2025 年６月期）
Consolidated / non-consolidatedConsolidated
| Item | Details |
|---|---|
| Net Sales | Not disclosed → ¥4,000 million |
| Operating profit | Not disclosed → ¥50 million |
| Ordinary income | Not disclosed → ¥55 million |
| Profit attributable to owners of the parent | Not disclosed → ¥30 million |
| Net income per share | Not disclosed → 1.15 yen and sen |
| Fiscal Period Covered | Fiscal year ending June 2026 |
| Period Covered | Full year |
| Publication date of previous forecast | 2025 年 8 月 13 日 |
| Previous-period results | 売上高 4,848 百万円、営業利益 △137 百万円、経常利益 △129 百万円、親会社株主に帰属する当期純利益 △210 百万円、１株当たり当期純利益 △8.05 円 銭（2025 年６月期） |
| Reason for the revision | 構造改革を継続し、医療DXを中心としたヘルスケア事業領域への経営資源の集中、健康補助食品事業の強化、事業ポートフォリオの再構築を進める。子会社の事業活動終了方針や希望退職制度の実施決定を踏まえ、セグメント別の受注・販売戦略・コスト改善などを反映して業績予想を公表した。 |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (2)
Details and amount of extraordinary lossDividend forecast revision
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.構造改革の進展、医療DXを中心としたヘルスケア事業領域への経営資源の集中、健康補助食品事業の強化、化粧品事業の見直し、子会社の事業活動終了方針、希望退職制度の実施決定などを業績予想に反映したためです。セグメント別には、受注基盤や新規契約、原価率・広告費・販促費の改善、事業終了に伴う一過性の発注などが挙げられています。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.